Genomic Selection Platform Market Report 2026

The genomic selection platform market size has grown rapidly in recent years. It will grow from $2.27 billion in 2025 to $2.66 billion in 2026 at a compound annual growth rate (CAGR) of 17.1%. The growth in the historic period can be attributed to expansion of molecular breeding programs, increasing availability of genotyping technologies, adoption of statistical genomics models, rising demand for faster breeding cycles, growing research investments in genetics.

The genomic selection platform market size is expected to see rapid growth in the next few years. It will grow to $4.96 billion in 2030 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to increasing adoption of genomic selection in agriculture, rising use of predictive analytics in breeding programs, expansion of sustainable crop and livestock development, growing integration of genomics with precision agriculture, advancement of cloud-native genomic platforms. Major trends in the forecast period include increasing adoption of AI-driven genomic prediction models, rising use of high-throughput genotyping platforms, growing integration of cloud-based breeding analytics, expansion of predictive breeding decision support systems, enhanced focus on trait-based selection accuracy.

The increasing adoption of personalized medicine is expected to propel the growth of the genomic selection platform market going forward. Personalized medicine focuses on tailoring treatments and prevention strategies to an individual’s genetic, lifestyle, and environmental factors. Its adoption is accelerating due to genomic advancements that enable precise identification of genetic differences and individualized therapies. Genomic selection platforms support personalized medicine by delivering detailed genomic insights that assist in customizing treatments. They minimize trial-and-error approaches by predicting patient responses, enhancing treatment effectiveness and patient outcomes. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), the FDA approved 26 personalized medicines in 2023, up from 12 approvals in 2022. Therefore, the increasing adoption of personalized medicine is driving the growth of the genomic selection platform market.

The rising crop yields are expected to propel the growth of the genomic selection platform market in the coming years. Crop yield refers to the quantity of agricultural output, such as grains, fruits, or vegetables, produced per unit of land. Crop yields are increasing due to advancements in agricultural biotechnology that improve plant genetics and resilience. Genomic selection platforms enhance crop yields by enabling accurate selection of high-performing plant varieties, making them well suited for modern agriculture and breeding programs. They reduce the time and cost associated with traditional breeding by delivering precise genetic predictions, boosting farm productivity, and strengthening food security. For instance, in May 2025, the Central Statistics Office, an Ireland-based agricultural statistics agency, reported that crops such as potato production increased by 46,100 tonnes annually to reach 368,300 tonnes in 2024. Potato yield increased by 1% to 39.6 tonnes per hectare. The potato cultivation area stood at 9,300 hectares in 2024, which was 1,100 hectares, or 13.2%, higher than in 2023. Therefore, increasing crop yields are contributing to the growth of the genomic selection platform market.

Leading companies operating in the genomic selection platform market are focusing on developing innovative solutions, such as targeted sequencing platforms, to improve trait prediction and accelerate breeding programs. Targeted sequencing platforms are genomic technologies designed to sequence specific regions of the genome rather than the entire genome. For instance, in October 2024, Element Biosciences Inc., a US-based life sciences technology company, launched Trinity, an advanced targeted sequencing platform that simplifies exome capture by integrating traditionally complex steps directly into its AVITI System. The platform removes the need for specialized equipment, reduces manual labor by up to five hours, and offers a one-hour hybridization option for same-day results, making it suitable for time-sensitive studies. Trinity also supports custom panels across applications such as oncology, respiratory diseases, and minimal residual disease (MRD), delivering faster, more cost-effective, and more accessible sequencing.

Major companies operating in the genomic selection platform market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., GE Healthcare Technologies Inc., Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., MGI Tech Co. Ltd., Azenta Inc., 10x Genomics Inc., Oxford Nanopore Technologies plc, Ultima Genomics Inc., Element Biosciences Inc., DNAnexus Inc., Deep Genomics Inc., Epigene Labs Inc., Quotient Therapeutics Inc., Evogene Ltd., Nebula Genomics Inc., Verinomics Inc., InEdita Bio Inc., GenEmbryomics Inc., Enigma Genomics Inc.

North America was the largest region in the genomic selection platform market in 2025. The regions covered in the genomic selection platform market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomic selection platform market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the genomic selection platform market by increasing costs of imported sequencing instruments, laboratory automation equipment, high-performance computing systems, and data storage hardware. Research institutes and biotechnology companies in North America and Europe are most affected due to dependence on imported advanced instrumentation, while Asia-Pacific faces higher costs for platform exports. These tariffs are increasing capital investment requirements and slowing technology upgrades. At the same time, they are encouraging regional manufacturing of genomics hardware, localized software development, and domestic service expansion, supporting long-term platform scalability.

The genomic selection platform market research report is one of a series of new reports that provides genomic selection platform market statistics, including genomic selection platform industry global market size, regional shares, competitors with a genomic selection platform market share, detailed genomic selection platform market segments, market trends and opportunities, and any further data you may need to thrive in the genomic selection platform industry. This genomic selection platform market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A genomic selection platform is a technology-based system that applies genome-wide genetic data to predict the performance or breeding potential of plants, animals, or microorganisms. It accelerates selective breeding by identifying individuals with preferred traits at early stages, thereby reducing reliance on time-consuming traditional evaluation methods. The platform integrates high-throughput genotyping, statistical modeling, and predictive analytics to support efficient and informed selection decisions.

The primary components of genomic selection platform are software, hardware, and services. Software refers to specialized computational tools and applications developed to analyze large-scale genomic data to support genomic selection in breeding programs. It can be deployed through on-premises or cloud-based modes and is applied in areas such as plant breeding, animal breeding, human genomics, and others. The key end-users include research institutes, biotechnology companies, agricultural organizations, and others.

The genomic selection platform market consists of revenues earned by entities by providing services such as genotyping, phenotyping, data analysis and interpretation, predictive modeling, breeding program management, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic selection platform market also includes sales of genotyping platforms, sequencing platforms, bioinformatics software, data analysis tools, marker-assisted selection tools, DNA extraction kits, and high-throughput genotyping assays. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.